EyePoint (EYPT)
Market Price (8/19/2026): $5.56 | Market Cap: $481.2 MilSector: Health Care | Industry: Biotechnology
EyePoint (EYPT)
Market Price (8/19/2026): $5.56Market Cap: $481.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -139% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.35 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -317 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11365% Expensive valuation multiplesP/SPrice/Sales ratio is 151x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -95%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -90% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1263% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9584%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -9727% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -77% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% Key risksEYPT key risks include [1] a heavy dependence on the clinical and regulatory success of its lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -139% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.35 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -317 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11365% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 151x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -95%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -90% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1263% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9584%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -9727% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -77% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% |
| Key risksEYPT key risks include [1] a heavy dependence on the clinical and regulatory success of its lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/17/2026
EyePoint (EYPT) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Topline Data from LUGANO Phase 3 Clinical Trial Missed Primary Endpoint.
EyePoint's stock experienced a sharp decline following the announcement on August 17, 2026, that its LUGANO pivotal Phase 3 clinical trial for DURAVYU in wet Age-related Macular Degeneration (AMD) failed to meet its primary endpoint in the full dataset. While an ad hoc analysis, excluding a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD, showed non-inferiority to aflibercept, the overall trial outcome was perceived negatively by the market, leading to a stock plunge of 63% to 71% around August 17-18, 2026.
2. Significant Analyst Downgrades and Price Target Reductions.
In direct response to the LUGANO trial results, multiple analyst firms issued substantial downgrades and slashed their price targets for EYPT. On August 18, 2026, RBC Capital downgraded EyePoint from 'Outperform' to 'Sector Perform' and drastically cut its price target by 86.49%, from $37.00 to $5.00. Similarly, Chardan Capital downgraded the stock from 'Buy' to 'Neutral' and reduced its price target from $65.00 to $5.00, reflecting a 92.31% decrease, citing increased regulatory uncertainty. Jefferies also lowered its price target from $30.00 to $8.00.
Show more
EyePoint (EYPT) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Topline Data from LUGANO Phase 3 Clinical Trial Missed Primary Endpoint.
EyePoint's stock experienced a sharp decline following the announcement on August 17, 2026, that its LUGANO pivotal Phase 3 clinical trial for DURAVYU in wet Age-related Macular Degeneration (AMD) failed to meet its primary endpoint in the full dataset. While an ad hoc analysis, excluding a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD, showed non-inferiority to aflibercept, the overall trial outcome was perceived negatively by the market, leading to a stock plunge of 63% to 71% around August 17-18, 2026.
2. Significant Analyst Downgrades and Price Target Reductions.
In direct response to the LUGANO trial results, multiple analyst firms issued substantial downgrades and slashed their price targets for EYPT. On August 18, 2026, RBC Capital downgraded EyePoint from 'Outperform' to 'Sector Perform' and drastically cut its price target by 86.49%, from $37.00 to $5.00. Similarly, Chardan Capital downgraded the stock from 'Buy' to 'Neutral' and reduced its price target from $65.00 to $5.00, reflecting a 92.31% decrease, citing increased regulatory uncertainty. Jefferies also lowered its price target from $30.00 to $8.00.
Show more
Updated on 8/17/2026
EyePoint (EYPT) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Topline Data from LUGANO Phase 3 Clinical Trial Missed Primary Endpoint.
EyePoint's stock experienced a sharp decline following the announcement on August 17, 2026, that its LUGANO pivotal Phase 3 clinical trial for DURAVYU in wet Age-related Macular Degeneration (AMD) failed to meet its primary endpoint in the full dataset. While an ad hoc analysis, excluding a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD, showed non-inferiority to aflibercept, the overall trial outcome was perceived negatively by the market, leading to a stock plunge of 63% to 71% around August 17-18, 2026.
2. Significant Analyst Downgrades and Price Target Reductions.
In direct response to the LUGANO trial results, multiple analyst firms issued substantial downgrades and slashed their price targets for EYPT. On August 18, 2026, RBC Capital downgraded EyePoint from 'Outperform' to 'Sector Perform' and drastically cut its price target by 86.49%, from $37.00 to $5.00. Similarly, Chardan Capital downgraded the stock from 'Buy' to 'Neutral' and reduced its price target from $65.00 to $5.00, reflecting a 92.31% decrease, citing increased regulatory uncertainty. Jefferies also lowered its price target from $30.00 to $8.00.
3. Wider Net Loss and Increased Operating Expenses in Fiscal Q2 2026.
EyePoint reported a net loss of $94.5 million, or $1.09 per share, for its fiscal Q2 2026, which ended June 30, 2026. This represented a significant increase from the $59.4 million net loss, or $0.85 per share, in fiscal Q2 2025. Operating expenses for the quarter rose by approximately 45% to $97.9 million, primarily driven by the ongoing DURAVYU Phase 3 clinical trials for wet AMD and Diabetic Macular Edema (DME), as well as manufacturing scale-up. The reported EPS of -$1.09 also missed analysts' consensus estimates of -$1.01 by $0.08.
4. Substantial Revenue Decline in Fiscal Q2 2026.
The company experienced a significant drop in revenue during fiscal Q2 2026, reporting total net revenue of $0.5 million, down from $5.3 million in the corresponding period of 2025, marking an approximate 90.5% decrease. This decline was primarily attributed to the prior recognition of remaining deferred revenue from a 2023 license agreement for YUTIQ product rights, with EyePoint generating no product sales during the quarter.
5. Notable Insider Selling Activity.
Around July 22, 2026, a Rule 144 filing disclosed an insider's plan to sell approximately $5.5 million worth of EyePoint shares, which were tied to option grants. This substantial planned insider selling activity likely contributed to negative investor sentiment and selling pressure on the stock.
Show less
EyePoint (EYPT) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Topline Data from LUGANO Phase 3 Clinical Trial Missed Primary Endpoint.
EyePoint's stock experienced a sharp decline following the announcement on August 17, 2026, that its LUGANO pivotal Phase 3 clinical trial for DURAVYU in wet Age-related Macular Degeneration (AMD) failed to meet its primary endpoint in the full dataset. While an ad hoc analysis, excluding a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD, showed non-inferiority to aflibercept, the overall trial outcome was perceived negatively by the market, leading to a stock plunge of 63% to 71% around August 17-18, 2026.
2. Significant Analyst Downgrades and Price Target Reductions.
In direct response to the LUGANO trial results, multiple analyst firms issued substantial downgrades and slashed their price targets for EYPT. On August 18, 2026, RBC Capital downgraded EyePoint from 'Outperform' to 'Sector Perform' and drastically cut its price target by 86.49%, from $37.00 to $5.00. Similarly, Chardan Capital downgraded the stock from 'Buy' to 'Neutral' and reduced its price target from $65.00 to $5.00, reflecting a 92.31% decrease, citing increased regulatory uncertainty. Jefferies also lowered its price target from $30.00 to $8.00.
3. Wider Net Loss and Increased Operating Expenses in Fiscal Q2 2026.
EyePoint reported a net loss of $94.5 million, or $1.09 per share, for its fiscal Q2 2026, which ended June 30, 2026. This represented a significant increase from the $59.4 million net loss, or $0.85 per share, in fiscal Q2 2025. Operating expenses for the quarter rose by approximately 45% to $97.9 million, primarily driven by the ongoing DURAVYU Phase 3 clinical trials for wet AMD and Diabetic Macular Edema (DME), as well as manufacturing scale-up. The reported EPS of -$1.09 also missed analysts' consensus estimates of -$1.01 by $0.08.
4. Substantial Revenue Decline in Fiscal Q2 2026.
The company experienced a significant drop in revenue during fiscal Q2 2026, reporting total net revenue of $0.5 million, down from $5.3 million in the corresponding period of 2025, marking an approximate 90.5% decrease. This decline was primarily attributed to the prior recognition of remaining deferred revenue from a 2023 license agreement for YUTIQ product rights, with EyePoint generating no product sales during the quarter.
5. Notable Insider Selling Activity.
Around July 22, 2026, a Rule 144 filing disclosed an insider's plan to sell approximately $5.5 million worth of EyePoint shares, which were tied to option grants. This substantial planned insider selling activity likely contributed to negative investor sentiment and selling pressure on the stock.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -58.6% change in EYPT stock from 4/30/2026 to 8/18/2026 was primarily driven by a -91.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.20 | 5.47 | -58.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 31 | 3 | -91.1% |
| P/S Multiple | 35.0 | 169.7 | 385.2% |
| Shares Outstanding (Mil) | 83 | 87 | -3.9% |
| Cumulative Contribution | -58.6% |
Market Drivers
4/30/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| EYPT | -58.6% | |
| Market (SPY) | 6.8% | 8.6% |
| Sector (XLV) | 16.3% | 2.7% |
Fundamental Drivers
The -59.5% change in EYPT stock from 1/31/2026 to 8/18/2026 was primarily driven by a -93.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.52 | 5.47 | -59.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 42 | 3 | -93.4% |
| P/S Multiple | 22.4 | 169.7 | 657.5% |
| Shares Outstanding (Mil) | 70 | 87 | -18.9% |
| Cumulative Contribution | -59.5% |
Market Drivers
1/31/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| EYPT | -59.5% | |
| Market (SPY) | 11.2% | 16.2% |
| Sector (XLV) | 10.1% | 10.2% |
Fundamental Drivers
The -44.3% change in EYPT stock from 7/31/2025 to 8/18/2026 was primarily driven by a -95.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.82 | 5.47 | -44.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56 | 3 | -95.0% |
| P/S Multiple | 12.2 | 169.7 | 1288.4% |
| Shares Outstanding (Mil) | 70 | 87 | -19.4% |
| Cumulative Contribution | -44.3% |
Market Drivers
7/31/2025 to 8/18/2026| Return | Correlation | |
|---|---|---|
| EYPT | -44.3% | |
| Market (SPY) | 22.4% | 13.1% |
| Sector (XLV) | 31.8% | 10.4% |
Fundamental Drivers
The -56.2% change in EYPT stock from 7/31/2023 to 8/18/2026 was primarily driven by a -93.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312023 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.50 | 5.47 | -56.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 40 | 3 | -93.0% |
| P/S Multiple | 11.8 | 169.7 | 1341.4% |
| Shares Outstanding (Mil) | 37 | 87 | -56.7% |
| Cumulative Contribution | -56.2% |
Market Drivers
7/31/2023 to 8/18/2026| Return | Correlation | |
|---|---|---|
| EYPT | -56.2% | |
| Market (SPY) | 73.6% | 13.0% |
| Sector (XLV) | 32.5% | 12.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EYPT Return | 86% | -71% | 560% | -68% | 145% | -73% | -26% |
| Peers Return | -31% | -39% | 14% | 96% | 55% | 5% | 54% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| EYPT Win Rate | 42% | 42% | 50% | 33% | 75% | 50% | |
| Peers Win Rate | 44% | 43% | 52% | 57% | 55% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| EYPT Max Drawdown | -50% | -83% | -63% | -76% | -55% | -73% | |
| Peers Max Drawdown | -50% | -60% | -50% | -48% | -44% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: OCUL, REGN, KOD, TARS, BLCO. See EYPT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/18/2026 (YTD)
How Low Can It Go
| Event | EYPT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -36.2% | -18.8% |
| % Gain to Breakeven | 56.7% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.8% | -7.8% |
| % Gain to Breakeven | 14.6% | 8.5% |
| Time to Breakeven | 7 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.4% | -9.5% |
| % Gain to Breakeven | 90.0% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.1% | -6.7% |
| % Gain to Breakeven | 78.9% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -55.3% | -24.5% |
| % Gain to Breakeven | 123.7% | 32.4% |
| Time to Breakeven | 277 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.2% | -33.7% |
| % Gain to Breakeven | 151.3% | 50.9% |
| Time to Breakeven | 1342 days | 140 days |
In The Past
EyePoint's stock fell -36.2% during the 2025 US Tariff Shock. Such a loss loss requires a 56.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | EYPT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -36.2% | -18.8% |
| % Gain to Breakeven | 56.7% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.4% | -9.5% |
| % Gain to Breakeven | 90.0% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.1% | -6.7% |
| % Gain to Breakeven | 78.9% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -55.3% | -24.5% |
| % Gain to Breakeven | 123.7% | 32.4% |
| Time to Breakeven | 277 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.2% | -33.7% |
| % Gain to Breakeven | 151.3% | 50.9% |
| Time to Breakeven | 1342 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -52.0% | -3.7% |
| % Gain to Breakeven | 108.3% | 3.9% |
| Time to Breakeven | 652 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -38.4% | -12.2% |
| % Gain to Breakeven | 62.4% | 13.9% |
| Time to Breakeven | 151 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -26.7% | -17.9% |
| % Gain to Breakeven | 36.4% | 21.8% |
| Time to Breakeven | 727 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -32.4% | -15.4% |
| % Gain to Breakeven | 47.8% | 18.2% |
| Time to Breakeven | 98 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -76.7% | -53.4% |
| % Gain to Breakeven | 329.0% | 114.4% |
| Time to Breakeven | 151 days | 1085 days |
In The Past
EyePoint's stock fell -36.2% during the 2025 US Tariff Shock. Such a loss loss requires a 56.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About EyePoint (EYPT)
EyePoint Pharmaceuticals (EYPT) is a pharmaceutical company dedicated to developing and commercializing innovative ophthalmic products for the treatment of various eye diseases. The company's core focus is on addressing conditions that can lead to significant vision impairment. EyePoint operates and distributes its products across the United States, China, and the United Kingdom.
The company's commercialized product portfolio includes ILUVIEN, an injectable, sustained-release micro-insert used for treating diabetic macular edema, and YUTIQ, an intravitreal implant designed for chronic non-infectious uveitis affecting the posterior segment of the eye. EyePoint also offers DEXYCU, a dexamethasone intraocular suspension that addresses post-operative ocular inflammation, such as that experienced following cataract surgery. In addition to these, EyePoint is developing pipeline candidates like EYP-1901 for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
EyePoint primarily serves ophthalmologists and their patients who require specialized treatments for complex and chronic eye conditions. Its target markets include patients suffering from diabetic macular edema, chronic uveitis, and individuals undergoing ocular surgery who require post-operative inflammation management. The company extends its reach and capabilities through strategic collaborations and commercial alliances with other entities in the pharmaceutical and medical device sectors.
AI Analysis | Feedback
Analogy 1: Regeneron for sustained-release eye disease treatments.
Analogy 2: The Bausch & Lomb for innovative, long-acting eye therapeutics.
AI Analysis | Feedback
- ILUVIEN: An injectable sustained-release micro-insert for the treatment of diabetic macular edema.
- YUTIQ: A fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye.
- DEXYCU: A dexamethasone intraocular suspension for post-operative ocular inflammation, including after cataract surgery.
- EYP-1901: A twice-yearly bioerodible formulation of a tyrosine kinase inhibitor in development for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
- YUTIQ50: A treatment in development for chronic non-infectious uveitis affecting the posterior segment of the eye.
AI Analysis | Feedback
EyePoint Pharmaceuticals, Inc. (EYPT), as a pharmaceutical company, primarily sells its products to other companies within the healthcare supply chain rather than directly to individual patients. The company's major customers are typically its distribution partners, licensees, and other pharmaceutical companies with whom it has strategic collaborations or commercial alliances for the commercialization of its ophthalmic products.
Based on the provided company description, EyePoint's major customers and partners involved in commercializing its products include:
- Alimera Sciences, Inc. (Symbol: ALIM) - Strategic collaboration, particularly mentioned in relation to ILUVIEN.
- Bausch & Lomb (Symbol: BLCO) - Strategic collaboration.
- Ocumension Therapeutics - Strategic collaboration, likely for markets such as China, as mentioned in the company's operating regions.
- ImprimisRx PA, Inc. (an entity of Harrow Health, Inc., Symbol: HROW) - Commercial alliance for the joint promotion of DEXYCU.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jay S. Duker, M.D., President & CEO and Board Director
Dr. Duker became President & CEO of EyePoint Pharmaceuticals in July 2023, having previously served as President and Chief Operating Officer, and Chief Strategic Scientific Officer after joining the company in 2020. He has dedicated over 30 years to ophthalmology across clinical research, business, and academic settings. Prior to EyePoint, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine from 2001 to 2021. He is also the founder of several successful businesses, including SurgiSite Boston, the Boston Image Reading Center (BIRC), and Hemera Biosciences. Hemera Biosciences, a gene therapy company, was acquired by Janssen in 2020. Additionally, he served as Chairman of the Board of Sesen Bio.
George O. Elston, Executive Vice President, Chief Financial Officer
Mr. Elston joined EyePoint in 2019 as Chief Financial Officer & Head of Corporate Development and was promoted to Executive Vice President in October 2023. He brings over 30 years of diverse financial and senior leadership experience in the biopharmaceutical sector. Before EyePoint, Mr. Elston served as Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he contributed to building the precommercial rare disease firm, leading to its eventual acquisition. He also held the position of President and Chief Executive Officer at 2X Oncology, Inc., where he developed the company from a spin-out into a multiprogram, clinical-stage organization. His career began in public accounting at PriceWaterhouseCoopers, and he held senior executive roles at Juniper Pharmaceuticals, Inc., KBI Biopharma, and Optherion, Inc.
Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer
Dr. Ribeiro was appointed Chief Medical Officer of EyePoint Pharmaceuticals in March 2024. A trained retinal specialist, he leads the Clinical Development, Clinical Operations, and Medical Safety teams. With over 15 years of experience, Dr. Ribeiro's background spans clinical practice, academia, and the pharmaceutical industry. Prior to joining EyePoint, he was the Vice President and Head of Clinical Development at Apellis Pharmaceuticals, where he played a key role in leading a global Phase 3 clinical program for Geographic Atrophy (GA) to U.S. FDA approval. He has also held leadership positions at several other pharmaceutical companies.
Ron Honig Esq., Chief Legal Officer & Company Secretary
Ron Honig serves as the Chief Legal Officer & Company Secretary for EyePoint Pharmaceuticals.
Michael Campbell, Chief Commercial Officer
Michael Campbell holds the position of Chief Commercial Officer at EyePoint Pharmaceuticals.
AI Analysis | Feedback
The key risks to EyePoint Pharmaceuticals (EYPT) primarily revolve around the successful development and commercialization of its lead pipeline candidate, DURAVYU™ (EYP-1901), as well as ongoing financial requirements and market competition.
- Clinical Trial Success and Regulatory Approval of DURAVYU™ (EYP-1901)
EyePoint Pharmaceuticals' future prospects are heavily dependent on the successful clinical development and regulatory approval of EYP-1901, now known as DURAVYU™, its lead product candidate. This investigational sustained-delivery treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) is currently in pivotal Phase 3 trials (LUGANO and LUCIA for wet AMD, COMO and CAPRI for DME), with topline data for wet AMD expected in mid-2026. Clinical trials are inherently expensive, time-consuming, and have uncertain outcomes, meaning delays or failures could significantly harm the business, financial condition, and prospects. For example, the product candidate previously failed to show significant improvement in a Phase 2 study for non-proliferative diabetic retinopathy. - Need for Additional Capital
As a biopharmaceutical company with significant research and development activities, EyePoint Pharmaceuticals has historically consumed substantial amounts of cash and anticipates a continued need for additional capital to fund its operations. If the company is unable to secure sufficient funding, it may be forced to curtail operations, reduce costs, and modify its business strategy, which could impede its growth and ability to bring innovative products to market. Analysts have also suggested that EyePoint may require further dilution to reach profitability, which is estimated to be several years away. - Competition and Market Adoption of DURAVYU™ and Existing Products
Even if DURAVYU™ achieves regulatory approval, it faces substantial competition in the crowded wet AMD and DME markets, where established anti-VEGF therapies like aflibercept are the standard of care. Its commercial viability will depend on demonstrating significant clinical differentiation, such as its sustained-delivery advantage, without requiring frequent supplemental treatments. Furthermore, EyePoint's business strategy relies on the successful commercialization and market acceptance of its approved products, including DEXYCU. Although the U.S. commercial rights for YUTIQ were acquired by Alimera Sciences, Inc., EyePoint still has an interest in its performance through potential royalties. Manufacturing inconsistencies and inadequate procedures, as highlighted by an FDA warning letter concerning YUTIQ at one of EyePoint's facilities, represent an additional risk that could impact product supply or regulatory standing.
AI Analysis | Feedback
null
AI Analysis | Feedback
EyePoint Pharmaceuticals, Inc. (EYPT) operates in several ophthalmic markets, addressing significant eye diseases. The addressable markets for their main products and developing therapies are detailed below.
### ILUVIEN
ILUVIEN, an injectable sustained-release micro-insert for the treatment of diabetic macular edema (DME), targets a substantial market. The global diabetic macular edema market was valued at approximately USD 5.4 billion in 2023 and is projected to reach USD 7.5 billion by 2034. Another estimate places the global DME market size at USD 3.33 billion in 2024, with a projection to reach USD 4.34 billion by 2032. Across the top seven major markets (US, EU4, UK, and Japan), the market reached USD 5.6 billion in 2024 and is expected to grow to USD 7.8 billion by 2035. The United States alone accounts for approximately 60% of the total DME market size across these seven major markets in 2023.
### YUTIQ
YUTIQ, a fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye, operates within the broader uveitis treatment market. The global uveitis treatment market was valued at USD 2.23 billion in 2023. More specifically, the market for posterior uveitis across the seven major markets (US, EU4, UK, and Japan) was valued at USD 438.5 million in 2024 and is anticipated to reach USD 723.4 million by 2035. Posterior uveitis is also expected to be the fastest-growing segment within the uveitis treatment market, with a projected compound annual growth rate (CAGR) of 9.4% over the forecast period.
### DEXYCU
DEXYCU, a dexamethasone intraocular suspension for the treatment of post-operative ocular inflammation, including treatment following cataract surgery, targets a growing market. The global post-operative cataract surgery inflammation treatment market was valued at USD 4.78 billion in 2025 and is projected to grow to USD 5.14 billion in 2026. Another source estimates this market at USD 5.2 billion in 2025, with a projection to reach USD 10.0 billion by 2035. In 2024, the market was valued at USD 4,562.25 million, with an expected increase to USD 7,821.22 million by 2032. North America held the largest share of this market in 2025. The United States specifically accounts for the largest market size in post-operative cataract surgery inflammation treatment.
### EYP-1901 (in development)
EYP-1901 is a developing therapy for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), each representing a significant addressable market.
* **Wet Age-Related Macular Degeneration (wet AMD):** The global wet AMD market size was USD 10.6 billion for 2025 and is projected to reach USD 16.7 billion by 2032. Across the seven major markets (US, EU4, UK, and Japan), the wet AMD market was approximately USD 7,783 million in 2023 and is anticipated to reach USD 18,317.5 million by 2035. The United States alone represented approximately 33% of the total 7MM market in 2023.
* **Diabetic Retinopathy (DR):** The global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to reach USD 15.48 billion by 2032. Other estimations show the global market at USD 10.23 billion in 2025, projected to increase to approximately USD 18.93 billion by 2035. North America was the dominant region in the global diabetic retinopathy market, holding a 37.8% share in 2024. The U.S. diabetic retinopathy market was valued at USD 3.02 billion in 2024 and is expected to reach USD 4.92 billion by 2032.
* **Retinal Vein Occlusion (RVO):** The global retinal vein occlusion treatment market was estimated at USD 2.48 billion in 2022 and is projected to reach USD 4.18 billion by 2030. Another report valued the market at USD 2.2 billion in 2023, with an estimated growth to USD 3.7 billion by 2032. The global market size was calculated at USD 2.82 billion in 2024 and is predicted to reach around USD 5.45 billion by 2034. North America held the largest revenue share, 41.20%, in 2022. The U.S. retinal vein occlusion treatment industry was approximately USD 858.5 million in 2023 and is projected to be worth around USD 1.93 billion by 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for EyePoint Pharmaceuticals (EYPT) over the next 2-3 years:
- Regulatory approval and subsequent commercial launch of DURAVYU for wet age-related macular degeneration (wet AMD). EyePoint's lead product candidate, DURAVYU (formerly EYP-1901), is currently in global Phase 3 pivotal clinical trials (LUGANO and LUCIA) for wet AMD. Enrollment for these trials was completed, and top-line data is anticipated in mid-2026, positioning a potential launch as a significant near-term revenue driver.
- Regulatory approval and subsequent commercial launch of DURAVYU for diabetic macular edema (DME). Following positive Phase 2 results from the VERONA clinical trial, EyePoint has initiated Phase 3 pivotal trials for DURAVYU in DME in 2026, with top-line data expected in the second half of 2027. The company views DME as a "three-billion-dollar market and growing," offering substantial revenue potential.
- Market adoption driven by DURAVYU's differentiated profile. DURAVYU offers a sustained-delivery treatment for retinal diseases, potentially requiring fewer injections (e.g., once every six months) compared to existing therapies. Its novel multi-mechanism of action, inhibiting all vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor (PDGFR), and interleukin-6 (IL-6) signaling, could provide a competitive advantage and drive market preference among retinal specialists, leading to increased sales.
- Potential expansion of DURAVYU into additional indications, such as non-proliferative diabetic retinopathy (NPDR). EyePoint has also evaluated DURAVYU in a Phase 2 PAVIA clinical trial for NPDR. Successful progression of this program to later stages and potential future regulatory approval would further broaden DURAVYU's market reach and contribute to additional revenue streams beyond wet AMD and DME.
AI Analysis | Feedback
Share Issuance
- In October 2025, EyePoint Pharmaceuticals priced an underwritten public offering of 11 million shares of common stock at $12.00 per share, along with pre-funded warrants for up to 1.5 million additional shares, expected to generate approximately $150 million in gross proceeds. The net proceeds were intended to advance the clinical development of Duravyu for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), support earlier-stage pipeline development initiatives, and for general corporate purposes.
- Prior to March 2026, EyePoint completed an upsized underwritten public offering of 14,636,363 shares of its common stock at $11.00 per share, generating gross proceeds of $161.0 million. The net proceeds were allocated to advance the clinical development of DURAVYU™ for wet AMD and DME, as well as to support its earlier stage pipeline development initiatives and for general corporate purposes.
- In November 2025, EyePoint Pharmaceuticals filed a prospectus supplement for a registered offering of up to $200 million in shares of its common stock, to be conducted under a Controlled Equity Offering Sales Agreement.
Inbound Investments
- In the fourth quarter of 2025, Parkman Healthcare Partners acquired 1,088,033 shares of EyePoint, representing a new investment valued at $19.88 million.
- On September 30, 2024, Vanguard Group Inc. acquired 273,728 shares of EyePoint Pharmaceuticals Inc. at a price of $7.99 each, increasing its total holdings in the company.
Outbound Investments
- In May 2023, EyePoint Pharmaceuticals entered into a definitive agreement for the sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 million. This included a $75 million upfront cash payment at closing and an additional $7.5 million in equal quarterly installments in 2024. EyePoint will also receive a low-to-mid double-digit royalty on Alimera’s U.S. net sales of YUTIQ above defined thresholds for the calendar years 2025-2028. This transaction allowed EyePoint to pay off outstanding bank debt and extend its cash runway.
Capital Expenditures
- EyePoint Pharmaceuticals reported capital expenditures of $2.15 million in 2022, $3.48 million in 2023, and $4.05 million in 2024.
- Capital expenditures for 2025 were reported as $4.1 million.
Peer Outperformance in Biotechnology
EYPT has outperformed 64% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that EYPT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
23%
of 460 industry peers · -51.7% return
3Y
37%
of 406 industry peers · -61.7% return
5Y
64%
of 364 industry peers · -43.9% return
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is EYPT's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.7% | 79.7% | 140.2% | CAH 411% · MCK 348% · COR 179% |
| Health Care Services | 20 | 20.0% | 41.9% | 9.5% | HIMS 302% · RDNT 143% · DGX 72% |
| Managed Health Care | 8 | 33.2% | -3.6% | 1.3% | OSCR 142% · HQY 64% · ELV 14% |
| Health Care Facilities | 24 | 11.9% | -3.3% | -15.7% | THC 289% · NHC 263% · ENSG 132% |
| Health Care Equipment | 51 | -2.3% | -9.2% | -18.9% | POCI 10738% · UFPT 396% · GKOS 288% |
| Health Care Supplies | 12 | 38.3% | -12.4% | -27.5% | LNTH 314% · HAE 81% · MMSI 31% |
| Pharmaceuticals | 63 | 3.1% | -1.7% | -31.9% | LQDA 2959% · INDV 1388% · ETON 1385% |
| Life Sciences Tools & Services | 108 | -8.4% | -32.7% | -70.6% | SNWV 1953% · ELMD 259% · MEDP 235% |
| Health Care Technology | 20 | -28.4% | -53.8% | -73.9% | SPOK 37% · HSTM -2% · VEEV -24% |
| Biotechnology ← | 365 | 6.6% | -27.4% | -77.2% | BRTX 106400% · DNTH 1803% · CELZ 1443% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 28.84 |
| Mkt Cap | 2.8 |
| Rev LTM | 329 |
| Op Inc LTM | -147 |
| FCF LTM | -52 |
| FCF 3Y Avg | -100 |
| CFO LTM | -42 |
| CFO 3Y Avg | -89 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 7.0% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Inc Chg LTM | -6.4% |
| Op Inc Chg 3Y Avg | 1.7% |
| Op Mgn LTM | -8.0% |
| Op Mgn 3Y Avg | -76.2% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 8.6% |
| CFO/Rev 3Y Avg | -54.6% |
| FCF/Rev LTM | 2.6% |
| FCF/Rev 3Y Avg | -58.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.8 |
| P/S | 5.4 |
| P/Op Inc | -4.7 |
| P/EBIT | -5.0 |
| P/E | -9.4 |
| P/CFO | 5.8 |
| Total Yield | -6.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -7.7% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 11.7% |
| 3M Rtn | 17.0% |
| 6M Rtn | 7.8% |
| 12M Rtn | 24.0% |
| 3Y Rtn | 81.4% |
| 1M Excs Rtn | 10.3% |
| 3M Excs Rtn | 10.7% |
| 6M Excs Rtn | -4.6% |
| 12M Excs Rtn | 4.8% |
| 3Y Excs Rtn | 4.9% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA208912 | DEXYCU KIT | dexamethasone | suspension | 2092018 | 93.3% | 111.5% | 129.8% | 78.8% | -53.2% |
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA208912 | DEXYCU KIT | dexamethasone | suspension | 2092018 | 93.3% | 111.5% | 129.8% | 78.8% | -53.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Business of developing and commercializing innovative products for the treatment of serious retinal | 31 | 43 | 46 | ||
| Dexamethasone intraocular suspension (DEXYCU) | 12 | 18 | |||
| Fluocinolone acetonide intravitreal implant (YUTIQ) | 28 | 17 | |||
| License and collaboration agreements | 0 | 1 | |||
| Royalty income | 1 | 1 | |||
| Total | 31 | 43 | 46 | 41 | 37 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Business of developing and commercializing innovative products for the treatment of serious retinal | -232 | -131 | -71 |
| Total | -232 | -131 | -71 |
Price Behavior
Price Behavior
| Market Price | $5.47 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 06/26/2008 | |
| Distance from 52W High | -71.0% | |
| 50 Days | 200 Days | |
| DMA Price | $12.97 | $14.10 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -57.8% | -61.2% |
| 3M | 1YR | |
| Volatility | 152.4% | 95.7% |
| Downside Capture | 516.00 | 240.12 |
| Upside Capture | 78.04 | 105.87 |
| Correlation (SPY) | 10.1% | 13.8% |
EYPT Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.18 | 0.36 | 0.59 | 1.21 | 0.88 | 1.14 |
| Up Beta | 6.06 | 2.62 | 1.74 | 1.40 | 1.58 | 1.14 |
| Down Beta | -1.53 | -0.67 | -0.56 | -0.90 | -0.19 | 0.67 |
| Up Capture | 104% | -25% | 41% | 163% | 112% | 282% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 20 | 32 | 61 | 130 | 361 |
| Down Capture | 319% | 41% | 94% | 177% | 102% | 110% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 14 | 23 | 31 | 65 | 122 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EYPT | |
|---|---|---|---|---|
| EYPT | -50.8% | 95.5% | -0.09 | - |
| Sector ETF (XLV) | 26.3% | 15.5% | 1.31 | 9.3% |
| Equity (SPY) | 20.4% | 12.8% | 1.17 | 12.9% |
| Gold (GLD) | 29.8% | 28.5% | 0.91 | 6.8% |
| Commodities (DBC) | 40.2% | 20.2% | 1.56 | -13.7% |
| Real Estate (VNQ) | 13.1% | 13.9% | 0.65 | 13.0% |
| Bitcoin (BTCUSD) | -45.4% | 42.7% | -1.30 | 2.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EYPT | |
|---|---|---|---|---|
| EYPT | -10.9% | 122.5% | 0.38 | - |
| Sector ETF (XLV) | 6.6% | 15.0% | 0.25 | 14.3% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 15.8% |
| Gold (GLD) | 19.8% | 18.6% | 0.87 | -0.1% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | -0.8% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 16.7% |
| Bitcoin (BTCUSD) | 7.1% | 52.6% | 0.32 | 12.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EYPT | |
|---|---|---|---|---|
| EYPT | -17.7% | 102.7% | 0.23 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.51 | 19.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 21.5% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 0.0% |
| Commodities (DBC) | 7.8% | 18.1% | 0.35 | 4.6% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 18.9% |
| Bitcoin (BTCUSD) | 59.9% | 66.0% | 1.00 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 5.0% | 11.8% | |
| 5/6/2026 | -2.9% | -0.9% | -10.8% |
| 3/4/2026 | -1.7% | -15.7% | -28.9% |
| 1/7/2026 | 3.0% | -5.5% | -24.5% |
| 11/5/2025 | -11.1% | -6.0% | 43.2% |
| 8/6/2025 | -2.8% | -1.3% | 9.1% |
| 5/7/2025 | -2.6% | -5.4% | 32.0% |
| 3/5/2025 | 8.2% | 20.9% | -11.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 13 |
| # Negative | 17 | 18 | 16 |
| Median Positive | 4.2% | 16.2% | 27.3% |
| Median Negative | -4.1% | -10.0% | -21.6% |
| Max Positive | 21.7% | 54.6% | 43.2% |
| Max Negative | -17.2% | -18.8% | -41.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 5.0% | 11.8% | |
| 5/6/2026 | -2.9% | -0.9% | -10.8% |
| 3/4/2026 | -1.7% | -15.7% | -28.9% |
| 1/7/2026 | 3.0% | -5.5% | -24.5% |
| 11/5/2025 | -11.1% | -6.0% | 43.2% |
| 8/6/2025 | -2.8% | -1.3% | 9.1% |
| 5/7/2025 | -2.6% | -5.4% | 32.0% |
| 3/5/2025 | 8.2% | 20.9% | -11.7% |
| 1/13/2025 | -7.1% | -10.3% | -24.7% |
| 11/7/2024 | -4.1% | -10.9% | -27.9% |
| 8/7/2024 | -4.1% | -13.0% | -10.6% |
| 5/8/2024 | -2.6% | 4.9% | -21.9% |
| 3/7/2024 | -1.7% | -14.2% | -21.2% |
| 1/10/2024 | -5.8% | 1.9% | 35.6% |
| 11/1/2023 | 20.3% | 27.1% | 3.8% |
| 8/2/2023 | 0.7% | -2.6% | -12.9% |
| 5/3/2023 | 21.7% | 0.2% | -8.2% |
| 3/2/2023 | -8.8% | -10.9% | 0.9% |
| 1/6/2023 | 0.3% | 54.6% | 39.3% |
| 11/2/2022 | -5.4% | -0.9% | -41.0% |
| 8/3/2022 | 10.1% | 16.6% | 7.8% |
| 5/4/2022 | 2.2% | -18.8% | -23.7% |
| 3/3/2022 | 15.3% | 42.3% | 23.9% |
| 11/3/2021 | 2.5% | 29.2% | 27.3% |
| 8/4/2021 | 1.8% | 15.9% | 28.4% |
| 5/5/2021 | 4.2% | -15.0% | -11.6% |
| 3/4/2021 | -17.2% | -9.9% | -6.8% |
| 1/11/2021 | -4.5% | -1.8% | 18.9% |
| 11/5/2020 | -2.4% | 3.9% | 29.1% |
| 8/5/2020 | -5.0% | -10.0% | -31.5% |
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 13 |
| # Negative | 17 | 18 | 16 |
| Median Positive | 4.2% | 16.2% | 27.3% |
| Median Negative | -4.1% | -10.0% | -21.6% |
| Max Positive | 21.7% | 54.6% | 43.2% |
| Max Negative | -17.2% | -18.8% | -41.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/14/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/12/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/16/2020 | 10-K |
| 09/30/2019 | 11/07/2019 | 10-Q |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zaderej, Karen L | Direct | Buy | 8182026 | 4.93 | 10,600 | 52,258 | 242,063 | Form | |
| 2 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 7022026 | 15.01 | 4,875 | Form | ||
| 3 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 4202026 | 15.00 | 2,437 | Form | ||
| 4 | Duker, Jay S | President and CEO | Family Trust | Buy | 3162026 | 13.15 | 1,500 | 19,724 | 1,323,664 | Form |
| 5 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 3052026 | 17.87 | 2,438 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zaderej, Karen L | Direct | Buy | 8182026 | 4.93 | 10,600 | 52,258 | 242,063 | Form | |
| 2 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 7022026 | 15.01 | 4,875 | Form | ||
| 3 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 4202026 | 15.00 | 2,437 | Form | ||
| 4 | Duker, Jay S | President and CEO | Family Trust | Buy | 3162026 | 13.15 | 1,500 | 19,724 | 1,323,664 | Form |
| 5 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 3052026 | 17.87 | 2,438 | Form | ||
| 6 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 2182026 | 15.00 | 2,437 | Form | ||
| 7 | Cormorant, Asset Management, LP | See Footnotes | Sell | 12082025 | 15.70 | 60,000 | 942,240 | 129,793,560 | Form | |
| 8 | Lurker, Nancy | Direct | Sell | 12052025 | 15.11 | 9,300 | 140,477 | 3,119,913 | Form | |
| 9 | Lurker, Nancy | Direct | Sell | 12012025 | 14.95 | 500 | 7,475 | 3,226,913 | Form | |
| 10 | Lurker, Nancy | Direct | Sell | 12012025 | 14.95 | 200 | 2,990 | 3,234,388 | Form | |
| 11 | Ribeiro, Ramiro | Chief Medical Officer | Direct | Sell | 11122025 | 11.61 | 2,722 | Form |
Investor Activity (13F)
Updated Aug 19, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Essex Woodlands Management, Inc. | $14.0 Mil | 5.6% | 5 | Hold | 13F |
| Cormorant Asset Management, LP | $106.5 Mil | 5.4% | 46 | Hold | 13F |
| 5AM Venture Management, LLC | $13.5 Mil | 3.8% | 20 | Hold | 13F |
| Artia Global Partners LP | $9.9 Mil | 2.2% | 48 | Hold | 13F |
| Commodore Capital LP | $36.4 Mil | 2.1% | 36 | New | 13F |
| Patient Square Capital LP | $10.2 Mil | 1.8% | 29 | Hold | 13F |
| Paradigm Biocapital Advisors LP | $40.5 Mil | 0.8% | 35 | TRIM -14.9% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | $106.5 Mil | 5.4% | 46 | Hold | 13F |
| Paradigm Biocapital Advisors LP | $40.5 Mil | 0.8% | 35 | TRIM -14.9% | 13F |
| Commodore Capital LP | $36.4 Mil | 2.1% | 36 | New | 13F |
| Essex Woodlands Management, Inc. | $14.0 Mil | 5.6% | 5 | Hold | 13F |
| 5AM Venture Management, LLC | $13.5 Mil | 3.8% | 20 | Hold | 13F |
| Patient Square Capital LP | $10.2 Mil | 1.8% | 29 | Hold | 13F |
| Artia Global Partners LP | $9.9 Mil | 2.2% | 48 | Hold | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/18/2026